| Autor: |
Koay WLA; Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.; Department of Pediatrics, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA., Xiao J; Department of Biostatistics and Bioinformatics and Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA., Temprosa M; Department of Biostatistics and Bioinformatics and Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA., Happ LP; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA., Monroe AK; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA., Castel AD; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA., Rakhmanina NY; Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.; Department of Pediatrics, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA.; Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, USA. |
| Abstrakt: |
This study explored virological outcomes of two-drug (2DRs) and three-drug (3DRs) antiretroviral regimens in adults with HIV in the DC Cohort. We analyzed 310 treatment-experienced adults with sustained HIV RNA ≤50 copies/mL at baseline, 53 of whom switched to 2DRs and 257 continued 3DRs. Adults on 2DRs and 3DRs had similar demographics (median age 53.3 years, 76.8% cisgender male, 76.1% Black). Adults on 2DRs had more participants with ≥2 comorbidities (62.3% vs. 42.8%, p = .019), had a longer time since HIV diagnosis (median years 20.4 vs. 13.2, p = .017), and received the regimen of interest for a shorter duration (median years 1.3 vs. 3.3, p < .001) compared with adults on 3DRs. Adults receiving 2DRs had a higher, although nonsignificant, risk for virological failure (two consecutive HIV RNA ≥50 copies/mL) at 24 months follow-up than adults on 3DRs (6.7% vs. 1.7%, respectively; p = .10). Future analysis of the effectiveness of 2DRs is needed. |
